| Completed | 3 | 841 | Europe, US, RoW | PP6M, R092670, PP3M 350 mg eq., PP3M 525 mg eq., PP1M, Placebo | Janssen Research & Development, LLC | Schizophrenia | 05/20 | 05/20 | | |
2018-004532-30: A 24 month Open-Label, international study of paliperidone 6 month formulation in patients with who have completed study R092670PSY3015 Schizophrenia is a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs). |
|
|
| Not yet recruiting | 3 | 180 | Europe | 1092mg paliperidone palmitate extended release suspension for injection (eq. 700 mg paliperidone), 1560 mg paliperidone palmitate extended release suspension for injection (eq. 1000 mg paliperidone), R092670, Prolonged-release suspension for injection in pre-filled syringe | Janssen-Cilag International NV, JANSSEN CILAG INTERNATIONAL NV, Janssen Research & Development, LLC, Janssen-Cilag SpA, Janssen-Cilag International NV | Schizophrenia, Schizophrenia, a mental illness with a number of symptoms, including disorganised thinking and speech, hearing or seeing things that are not there and delusions (fixed, false beliefs), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT04072575: A Study of Paliperidone Palmitate 6-Month Formulation |
|
|
| Completed | 3 | 178 | Europe, RoW | PP6M injection Dose 1, R092670, PP6M injection Dose 2 | Janssen Research & Development, LLC | Schizophrenia | 05/22 | 05/22 | | |
